Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease

Katelyn Paz, Ryan Flynn, Jing Du, Jun Qi, Leo Luznik, Ivan Maillard, Kelli P. MacDonald, Geoffrey R. Hill, Jonathan S. Serody, William J Murphy, Peter T. Sage, Arlene H. Sharpe, David Miklos, Corey S. Cutler, John Koreth, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz, James E. Bradner, Ari M. MelnickBruce R. Blazar

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Patient outcomes for steroid-dependent or -refractory chronic graft-versus-host diesease (cGVHD) are poor, and only ibrutinib has been US Food and Drug Administration (FDA) approved for this indication. cGVHD is often driven by the germinal center (GC) reaction, in which T follicular helper cells interact with GC B cells to produce antibodies that are associated with disease pathogenesis. The transcriptional corepressor B-cell lymphoma 6 (BCL6) is a member of the Broad-complex, Tramtrack, and Bric-abrac/poxvirus and zinc finger (BTB/POZ) transcription factor family and master regulator of the immune cells in the GC reaction. We demonstrate that BCL6 expression in both donor T cells and B cells is necessary for cGVHD development, pointing to BCL6 as a therapeutic cGVHD target. A small-molecule BCL6 inhibitor reversed active cGVHD in a mouse model of multiorgan system injury with bronchiolitis obliterans associated with a robust GC reaction, but not in cGVHD mice with scleroderma as the prominent manifestation. For cGVHD patients with antibody-driven cGVHD, targeting of BCL6 represents a new approach with specificity for a master GC regulator that would extend the currently available second-line agents.

Original languageEnglish (US)
Pages (from-to)94-99
Number of pages6
JournalBlood
Volume133
Issue number1
DOIs
StatePublished - Jan 3 2019

Fingerprint

B-Cell Lymphoma
Graft vs Host Disease
Grafts
Germinal Center
Transplants
Molecules
Cells
B-Lymphocytes
Bronchiolitis Obliterans
Poxviridae
Co-Repressor Proteins
T-cells
Antibodies
Zinc Fingers
United States Food and Drug Administration
Helper-Inducer T-Lymphocytes
Refractory materials
Zinc
Transcription Factors
Steroids

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Paz, K., Flynn, R., Du, J., Qi, J., Luznik, L., Maillard, I., ... Blazar, B. R. (2019). Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 133(1), 94-99. https://doi.org/10.1182/blood-2018-03-839993

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. / Paz, Katelyn; Flynn, Ryan; Du, Jing; Qi, Jun; Luznik, Leo; Maillard, Ivan; MacDonald, Kelli P.; Hill, Geoffrey R.; Serody, Jonathan S.; Murphy, William J; Sage, Peter T.; Sharpe, Arlene H.; Miklos, David; Cutler, Corey S.; Koreth, John; Antin, Joseph H.; Soiffer, Robert J.; Ritz, Jerome; Bradner, James E.; Melnick, Ari M.; Blazar, Bruce R.

In: Blood, Vol. 133, No. 1, 03.01.2019, p. 94-99.

Research output: Contribution to journalArticle

Paz, K, Flynn, R, Du, J, Qi, J, Luznik, L, Maillard, I, MacDonald, KP, Hill, GR, Serody, JS, Murphy, WJ, Sage, PT, Sharpe, AH, Miklos, D, Cutler, CS, Koreth, J, Antin, JH, Soiffer, RJ, Ritz, J, Bradner, JE, Melnick, AM & Blazar, BR 2019, 'Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease', Blood, vol. 133, no. 1, pp. 94-99. https://doi.org/10.1182/blood-2018-03-839993
Paz, Katelyn ; Flynn, Ryan ; Du, Jing ; Qi, Jun ; Luznik, Leo ; Maillard, Ivan ; MacDonald, Kelli P. ; Hill, Geoffrey R. ; Serody, Jonathan S. ; Murphy, William J ; Sage, Peter T. ; Sharpe, Arlene H. ; Miklos, David ; Cutler, Corey S. ; Koreth, John ; Antin, Joseph H. ; Soiffer, Robert J. ; Ritz, Jerome ; Bradner, James E. ; Melnick, Ari M. ; Blazar, Bruce R. / Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. In: Blood. 2019 ; Vol. 133, No. 1. pp. 94-99.
@article{830f42a0e63b4c42871e25850005dc22,
title = "Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease",
abstract = "Patient outcomes for steroid-dependent or -refractory chronic graft-versus-host diesease (cGVHD) are poor, and only ibrutinib has been US Food and Drug Administration (FDA) approved for this indication. cGVHD is often driven by the germinal center (GC) reaction, in which T follicular helper cells interact with GC B cells to produce antibodies that are associated with disease pathogenesis. The transcriptional corepressor B-cell lymphoma 6 (BCL6) is a member of the Broad-complex, Tramtrack, and Bric-abrac/poxvirus and zinc finger (BTB/POZ) transcription factor family and master regulator of the immune cells in the GC reaction. We demonstrate that BCL6 expression in both donor T cells and B cells is necessary for cGVHD development, pointing to BCL6 as a therapeutic cGVHD target. A small-molecule BCL6 inhibitor reversed active cGVHD in a mouse model of multiorgan system injury with bronchiolitis obliterans associated with a robust GC reaction, but not in cGVHD mice with scleroderma as the prominent manifestation. For cGVHD patients with antibody-driven cGVHD, targeting of BCL6 represents a new approach with specificity for a master GC regulator that would extend the currently available second-line agents.",
author = "Katelyn Paz and Ryan Flynn and Jing Du and Jun Qi and Leo Luznik and Ivan Maillard and MacDonald, {Kelli P.} and Hill, {Geoffrey R.} and Serody, {Jonathan S.} and Murphy, {William J} and Sage, {Peter T.} and Sharpe, {Arlene H.} and David Miklos and Cutler, {Corey S.} and John Koreth and Antin, {Joseph H.} and Soiffer, {Robert J.} and Jerome Ritz and Bradner, {James E.} and Melnick, {Ari M.} and Blazar, {Bruce R.}",
year = "2019",
month = "1",
day = "3",
doi = "10.1182/blood-2018-03-839993",
language = "English (US)",
volume = "133",
pages = "94--99",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease

AU - Paz, Katelyn

AU - Flynn, Ryan

AU - Du, Jing

AU - Qi, Jun

AU - Luznik, Leo

AU - Maillard, Ivan

AU - MacDonald, Kelli P.

AU - Hill, Geoffrey R.

AU - Serody, Jonathan S.

AU - Murphy, William J

AU - Sage, Peter T.

AU - Sharpe, Arlene H.

AU - Miklos, David

AU - Cutler, Corey S.

AU - Koreth, John

AU - Antin, Joseph H.

AU - Soiffer, Robert J.

AU - Ritz, Jerome

AU - Bradner, James E.

AU - Melnick, Ari M.

AU - Blazar, Bruce R.

PY - 2019/1/3

Y1 - 2019/1/3

N2 - Patient outcomes for steroid-dependent or -refractory chronic graft-versus-host diesease (cGVHD) are poor, and only ibrutinib has been US Food and Drug Administration (FDA) approved for this indication. cGVHD is often driven by the germinal center (GC) reaction, in which T follicular helper cells interact with GC B cells to produce antibodies that are associated with disease pathogenesis. The transcriptional corepressor B-cell lymphoma 6 (BCL6) is a member of the Broad-complex, Tramtrack, and Bric-abrac/poxvirus and zinc finger (BTB/POZ) transcription factor family and master regulator of the immune cells in the GC reaction. We demonstrate that BCL6 expression in both donor T cells and B cells is necessary for cGVHD development, pointing to BCL6 as a therapeutic cGVHD target. A small-molecule BCL6 inhibitor reversed active cGVHD in a mouse model of multiorgan system injury with bronchiolitis obliterans associated with a robust GC reaction, but not in cGVHD mice with scleroderma as the prominent manifestation. For cGVHD patients with antibody-driven cGVHD, targeting of BCL6 represents a new approach with specificity for a master GC regulator that would extend the currently available second-line agents.

AB - Patient outcomes for steroid-dependent or -refractory chronic graft-versus-host diesease (cGVHD) are poor, and only ibrutinib has been US Food and Drug Administration (FDA) approved for this indication. cGVHD is often driven by the germinal center (GC) reaction, in which T follicular helper cells interact with GC B cells to produce antibodies that are associated with disease pathogenesis. The transcriptional corepressor B-cell lymphoma 6 (BCL6) is a member of the Broad-complex, Tramtrack, and Bric-abrac/poxvirus and zinc finger (BTB/POZ) transcription factor family and master regulator of the immune cells in the GC reaction. We demonstrate that BCL6 expression in both donor T cells and B cells is necessary for cGVHD development, pointing to BCL6 as a therapeutic cGVHD target. A small-molecule BCL6 inhibitor reversed active cGVHD in a mouse model of multiorgan system injury with bronchiolitis obliterans associated with a robust GC reaction, but not in cGVHD mice with scleroderma as the prominent manifestation. For cGVHD patients with antibody-driven cGVHD, targeting of BCL6 represents a new approach with specificity for a master GC regulator that would extend the currently available second-line agents.

UR - http://www.scopus.com/inward/record.url?scp=85059459767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059459767&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-03-839993

DO - 10.1182/blood-2018-03-839993

M3 - Article

C2 - 30279226

AN - SCOPUS:85059459767

VL - 133

SP - 94

EP - 99

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -